| Design | International RCT, n=344 |
| Published | 2017 (NEJM) |
| Result | Angiotensin II increased MAP response at 3 hours (69.9% vs 23.4%) in vasodilatory shock refractory to high-dose conventional vasopressors. No significant mortality difference at 28 days. |
| Practice impact | Led to FDA approval of angiotensin II as a vasopressor; now used as a third-line agent in catecholamine-refractory vasodilatory shock. |
Source: The Bottom Line